Injecto Polymers trading supplies 50.36% of FY2026 operating revenue

Injecto Polymers Limited derived Rs 189.1221 crore, or 50.36% of revenue from operations, from trading in FY2026, compared with Rs 186.4092 crore, or 49.64%, from manufacturing. Trading overtook manufacturing in FY2025 and remained the larger stream in FY2026, while Injecto Polymers pursues manufacturing-capacity additions at Unit I.

Why did Injecto Polymers become trading-led?

Injecto Polymers became trading-led in FY2025 because trading revenue increased more quickly than manufacturing revenue. Trading revenue rose from Rs 30.152 crore, or 27.65% of revenue from operations in FY2024, to Rs 139.0892 crore, or 53.19%, in FY2025. Manufacturing revenue rose from Rs 78.8959 crore, or 72.35%, to Rs 122.3881 crore, or 46.81%, over the same period.

The FY2026 mix shifted marginally towards manufacturing but did not restore manufacturing as the majority activity. Trading revenue increased by Rs 50.0329 crore to Rs 189.1221 crore in FY2026, while manufacturing revenue increased by Rs 64.0211 crore to Rs 186.4092 crore. Trading's share therefore declined by 2.83 percentage points from FY2025, but remained 0.72 percentage points higher than manufacturing's 49.64% share.

The comparison marks a substantial change in the composition of Rs 375.5313 crore of FY2026 revenue from operations. Manufacturing was the larger activity by 44.70 percentage points in FY2024, whereas trading was larger by 6.38 percentage points in FY2025 and by 0.72 percentage points in FY2026. The continuation of a trading majority depends on trading sales remaining above manufacturing sales, rather than on total revenue alone.

What risks accompany Injecto Polymers' trading-led revenue?

Injecto Polymers says dependence on trading exposes it to volatility in traded-goods prices, demand-supply fluctuations, higher inventory requirements, low margins, counterparty defaults and competition resulting from low barriers to entry. These risks apply to the segment that accounted for Rs 189.1221 crore of FY2026 revenue from operations, so adverse developments in trading could affect revenue, cash flows, results of operations and financial condition.

Trading revenue is also exposed to the company's customer concentration. Its top 10 customers contributed Rs 150.4689 crore, or 40.07%, of FY2026 revenue from operations, and its top five customers contributed Rs 114.5745 crore, or 30.51%. The top-10 share was slightly below 40.63% in FY2025 but above 37.20% in FY2024, meaning a limited customer group continued to account for about two-fifths of revenue.

Manufacturing has separate input-cost exposure because Injecto Polymers uses polypropylene, low-density polyethylene, high-density polyethylene, polypropylene resin, calcium carbonate, ultraviolet stabilisers, pigments and colour masterbatch. The company says prices and availability are influenced by crude-oil movements, inflation, global supply-demand imbalances, logistics constraints and geopolitical developments. It seeks to manage these factors through domestic supplier relationships, sourcing diversification and inventory optimisation, but says an inability to pass on a sharp cost increase promptly could affect margins and cash flows.

Can capacity additions make Injecto Polymers manufacturing-led again?

Injecto Polymers has disclosed a manufacturing expansion plan, but it does not assure that manufacturing revenue will again exceed trading revenue. Combined installed capacity was 10,870 metric tonnes, or MT, as of March 31, 2026, and average production was 10,358 MT, equal to average capacity utilisation of 95.29%. A manufacturing-led mix would require manufacturing sales to grow faster than trading sales after capacity becomes available.

Injecto Polymers commenced a trial run of 120 MT of expanded Phase III capacity at Unit I on July 1, 2026. The company says completion of an additional 1,200 MT under Phase III will add 2,400 MT of capacity, while Phase IV is in process and is expected to add a further 4,800 MT. It states that installed capacity will rise to 18,070 MT following commissioning of Phase III and proposed Phase IV.

The expansion plan also contains an execution condition: Unit II is operated under a leave-and-licence arrangement with group company Hind Polyfabs Private Limited. Unit II had installed capacity of 2,400 MT and average capacity utilisation of 95.63% as of March 31, 2026. The arrangement began on June 1, 2024 for 11 months, and its renewal clause permits successive 11-month extensions for up to seven years.

What do utilisation and geographic concentration mean for the plan?

Injecto Polymers' reported factory utilisation shows that the existing combined capacity was substantially used before the planned additions. Combined utilisation increased from 79.46% in FY2024 to 99.58% in FY2025, before declining to 95.29% in FY2026. Over those three financial years, installed capacity rose from 8,470 MT to 10,470 MT and then 10,870 MT, while average production increased from 6,730 MT to 10,426 MT before easing to 10,358 MT.

Unit I, including Phase I and Phase II, had installed capacity of 8,470 MT in each of FY2024, FY2025 and FY2026. Its utilisation rose from 79.46% in FY2024 to 99.87% in FY2025 and was 95.19% in FY2026. The company notes that tape-plant production varies with denier, a measure of fibre thickness, because higher denier increases output weight at a given line speed; output tonnage alone therefore does not establish operating efficiency.

Geographic concentration could affect the sales needed to absorb higher capacity. West Bengal generated Rs 320.2098 crore, or 85.27%, of FY2026 revenue from operations, while other eastern states generated Rs 26.4463 crore, or 7.04%. Together, eastern India accounted for 92.31% of FY2026 operating revenue, compared with Rs 28.8752 crore, or 7.69%, from the rest of India.

Injecto Polymers says its current capacity allows it to cater exclusively to existing eastern-India clients. It states that expansion from 13,270 MT to 18,070 MT would equip it to serve clients in additional regions, but gives no assurance that diversification will succeed or sufficiently offset geographic concentration. Manufacturing-led growth would consequently depend on commissioning capacity, maintaining production and securing demand beyond the existing customer base.

Conclusion

Injecto Polymers' FY2026 revenue composition remained marginally trading-led, with Rs 189.1221 crore from trading against Rs 186.4092 crore from manufacturing. That position followed the FY2025 reversal from a manufacturing majority in FY2024, while top-10 customers accounted for 40.07% of FY2026 revenue and West Bengal accounted for 85.27%.

The disclosed milestone to watch is commissioning of Phase III and the proposed Phase IV, which Injecto Polymers says would bring installed capacity to 18,070 MT. Whether that changes the revenue mix remains unresolved because it requires manufacturing sales to outpace trading sales, continued access to Unit II under its renewable arrangement, and demand from regions beyond eastern India.